Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015612
Filing Date
2024-11-14
Accepted
2024-11-14 07:03:27
Documents
55
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q plx-20240930x10q.htm   iXBRL 10-Q 1102511
2 EX-31.1 plx-20240930xex31d1.htm EX-31.1 12571
3 EX-31.2 plx-20240930xex31d2.htm EX-31.2 12740
4 EX-32.1 plx-20240930xex32d1.htm EX-32.1 6816
5 EX-32.2 plx-20240930xex32d2.htm EX-32.2 6838
6 GRAPHIC plx-20240930x10q005.jpg GRAPHIC 58451
7 GRAPHIC plx-20240930x10q007.jpg GRAPHIC 52258
8 GRAPHIC plx-20240930x10q008.jpg GRAPHIC 33083
  Complete submission text file 0001558370-24-015612.txt   4864185

Data Files

Seq Description Document Type Size
9 EX-101.SCH plx-20240930.xsd EX-101.SCH 32008
10 EX-101.CAL plx-20240930_cal.xml EX-101.CAL 44430
11 EX-101.DEF plx-20240930_def.xml EX-101.DEF 113028
12 EX-101.LAB plx-20240930_lab.xml EX-101.LAB 236746
13 EX-101.PRE plx-20240930_pre.xml EX-101.PRE 191938
58 EXTRACTED XBRL INSTANCE DOCUMENT plx-20240930x10q_htm.xml XML 647547
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 241457125
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)